Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251380 | 0.86 | ALOX5AP (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL24251587 | 0.85 | HPGD (0.44) | RAB9ANPC1SMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL24251588 | 0.84 | HSP90AA1 (0.44) | SCD5SCDHCRTR1HCRTR2 | |
| SCHEMBL24251385 | 0.84 | SPR (0.40) | SCD5SMN1; SMN2SPRHCRTR1HCRTR2 | |
| SCHEMBL24251389 | 0.83 | HCRTR1 (0.39) | SCD5HCRTR1HCRTR2 | |
| SCHEMBL24251549 | 0.80 | SPR (0.36) | SPRHCRTR1HCRTR2 | |
| SCHEMBL24251391 | 0.80 | CYP3A4 (0.37) | SMN1; SMN2SPRHCRTR1HCRTR2 | |
| SCHEMBL23355438 | 0.79 | PDE4B (0.35) | MAPT | |
| SCHEMBL24251498 | 0.78 | SPR (0.41) | SPR | |
| SCHEMBL24251538 | 0.77 | SPR (0.42) | MAPTSPRHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | SCD5 3838/4885RAB9A 1451/4885NPC1 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.